SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
3 references·0 citing·16 second hop
Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung (2011)Cost‐effectiveness of epidermal growth fa…Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer (2010)Economic Analysis: Randomized…Health state utilities for non small cell lung cancer (2008)Health state utilities for no…Health Economics: An Introduction for Clinicians (1987)Health Economics: An Introduc…Economics of coronary artery bypass grafting. (1985)Physician utilization. The state of research about physicians' practice patterns. (1985)Use and Misuse of the Term “Cost Effective” in Medicine (1986)Mortality Risks Induced by Economic Expenditures (1990)Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist (1993)Costs of disorders of the brain in Europe (2007)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Evaluation of Trends in the Cost of Initial Cancer Treatment (2008)An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis (2019)Measurement of health state utilities for economic appraisal (1986)Quality of life and pharmacoeconomics in clinical trials (1996)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting (2013)Health state utilities in non–small cell lung cancer: An international study (2016)Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer (2018)
this work references cited by second hop

References

  • 2008Health state utilities for non small cell lung cancer407 cited
  • 1987Health Economics: An Introduction for Clinicians112 cited
  • 2010Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer76 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work